Synairgen Share Discussion Threads

[richardjohn10] 26/7/2020 11:23

I'm very conservative with my goalsFar too many shares get over hyped and valuations never come off!I hope I'm way out and it's £20 though lol

[dovey21] 26/7/2020 11:16

And the rest buddy! :-)...£8 likely with £10 or more not inconceivable IMO.

[richardjohn10] 26/7/2020 10:11

My £6 hopes realistic then

[simon_64] 26/7/2020 09:45

Boris will jump to Trumps tune he is a muppet umatingytribe.

[amaretto1] 26/7/2020 09:41

A profit is only a profit when banked !! And NOT before

[oldvic] 26/7/2020 09:37

good morning Lord Nobby
please could you share some coins
Regards
Oldvic

[bmnsa] 26/7/2020 09:25

Three university professors become overnight MILLIONAIRES after finding 'major breakthrough' in Covid drug for treating patients with lung conditions

Ratko Djukanovic, Stephen Holgate and Donna Davies are now millionaires

Shares in their company Synairgen skyrocketed by 3,000 per cent overnight

It came after a 'major breakthrough' in a coronavirus drug trialled by Synairgen

Trial found 79 per cent of patients given the drug less likely to be seriously ill
By EMER SCULLY FOR MAILONLINE

PUBLISHED: 16:02, 25 July 2020 | UPDATED: 16:07, 25 July 2020


In a study of 101 people, coronavirus patients who were given a special formula of the professor's interferon drug, SNG001, were two or three more times more likely to recover than those given a placebo.

Patients given the drug directly into their airways via a nebuliser, a powerful inhaler, were 79 percent less likely to become seriously ill with the disease.

For those on the drug breathlessness was 'markedly reduced'.

Richard Marsden, Synairgen’s chief executive, told The Guardian: '[For them] it doesn't get better than seeing a drug you created treating real patients, and the side-effect of that is you make money… If people are clever and find something useful, they should get rewarded economically.'

The three professors, who first discovered people with asthma and chronic lung disease lack a protein called interferon beta in 2004, are now worth more than a million pounds each.

Interferon beta can help the body fight off the common cold. If the missing protein is replaced the body's natural defences are better able to beat a viral infection.

The clinical trial results were published on July 21, and by lunchtime Synairgen shares were up by 540 per cent.

The company directors' combined 2.6 per cent stake has now been valued at more than £7million.

Marsden, who holds 0.3 per cent of stocks, said the 204p share price at close of day Friday was 'reasonable'.



'It is a major breakthrough in the treatment of hospitalised Covid-19 patients,' Marsden added. 'We couldn't have expected much better [trial] results than these.'

The trial has now been expanded to patients suffering with milder coronavirus symptoms at home, in an effort to lower the number of cases in hospitals.

And the drug manufacturer Rentschler has been ordered to start producing more than a million doses of the drug ahead of an anticipated second wave in the winter.


Synairgen started setting up their clinical trial in February and March to ensure a drug was ready by the time coronavirus became a problem in the UK.

But others haven't been so lucky, with a former long-suffering investor selling their fund holdings last month for less than £10m, a quarter of their value today.

Neil Woodford, who was known for taking bets and investing on early-stage medical stocks, was one of the biggest investors in Synairgen through his equity income fund.

The next stage for Synairgen is gaining the approval of worldwide medical regulators so the treatment can be brought to market.

Independent experts previously said Synairgen's trial would 'represent by far the biggest breakthrough in Covid-19 treatment to date' if the results are verified.

The only drug scientifically proven to treat the disease at present is a £5 steroid known as dexamethasone, which slashes death rates by up to a third.

Southampton-based Synairgen is a publicly traded firm, meaning it was obligated to release the preliminary results due to stock market rules.

The trial involved 101 Covid-19 patients who had been admitted at nine UK hospitals and required oxygen support. Half of the recruits were given the drug, while the rest took a placebo.

The trial was carried out on a double blind basis, meaning neither the researchers nor the 101 patients knew who was receiving SNG001.

Three people died after being randomly assigned the placebo, while there were no deaths among those who received the drug, Synairgen said.

Studies have shown key high risk groups for Covid-19, including older people and those with some chronic diseases have lower levels of interferon beta.

Separate trials in asthmatic patients have shown SNG001 is well-tolerated, boosts the lungs anti-viral defences and helps lung function during cold or flu infection.

The inhaler turns SNG001 into a fine mist so it can be inhaled deep into the lungs, with the hope it will trigger a stronger, more targeted anti-viral response.

Interferon beta is already used as an injection to boost the immune response of people with multiple sclerosis.

The trial's chief investigator, Tom Wilkinson, professor of respiratory medicine at the University of Southampton, said if the results are replicated in larger studies it will be 'a game changer'.

He added: 'The results confirm our belief that interferon beta, a widely known drug that, by injection, has been approved for use in a number of other indications, has huge potential as an inhaled drug to be able to restore the lungs' immune response, enhancing protection, accelerating recovery and countering the impact of Sars-CoV-2 virus.'

Stephen Holgate CBE, professor of immunopharmacology at the University of Southampton, said recognising that the coronavirus 'is known to have evolved to evade the initial anti-viral response of the lung' was a valuable insight.

'Our treatment of giving high local concentrations of interferon beta, a naturally occurring antiviral protein, restores the lungs ability to neutralise the virus,' added Professor Holgate, who is also the co-founder of Synairgen.

He said it would work on 'any mutation of the virus or co-infection with another respiratory virus such as RSV or influenza, as could be encountered in the winter if there is a resurgence of Covid-19'.

Reacting to the findings, Professor Francois Balloux, a geneticist at University College London, tweeted: 'Preliminary results from a clinical trial suggest interferon beta reduces the risk of developing severe #COVID19 disease by 79 per cent.

'If confirmed, this would represent by far the biggest breakthrough in #COVID19 treatment to date.'

Naveed Sattar, professor of metabolic medicine at the University of Glasgow, added: 'The results seem very impressive, and although accepted that the trial is small with just over 100 participants, a 79 per cent reduction in disease severity could be a game changer.